RCT Tries Dissolution Case Involving Inspirion Delivery Sciences LLC (IDS)

RCT recently tried a case to dissolve IDS to the Delaware Chancery Court. IDS holds a patent to technology that gives abuse deterrent characteristics to common opioid painkillers. The FDA has approved two such products thus far, including the only immediate release abuse deterrent opioid product approved by the FDA to date. Unfortunately, deadlock and governance dysfunction within IDS have crippled the company and no progress has been made on new product development. By dissolving IDS, RCT’s client, the innovator of the technology, hopes to get the promising technology back on track to help solve the opioid crisis and maximize value for IDS’s investors.

Prior results do not guarantee a similar outcome.